17 General Introduction 1 22. Perl, T.M., et al., Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med, 2002. 346(24): p. 1871-7. 23. van Rijen, M., et al., Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev, 2008. 2008(4): p. Cd006216. 24. Bode, L.G., et al., Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med, 2010. 362(1): p. 9-17. 25. WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe; 2022. 26. Vos, M.C., et al., 5 years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect Control Hosp Epidemiol, 2009. 30(10): p. 977-84. 27. Wertheim, H.F., et al., Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect, 2004. 56(4): p. 321-5. 28. Dutch Working Party on Infection Prevention (WIP) (2017) MRSA hospitals. 29. Stefani, S., et al., Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents, 2012. 39(4): p. 273-82. 30. Baud, O., et al., First outbreak of community-acquired MRSA USA300 in France: failure to suppress prolonged MRSA carriage despite decontamination procedures. Eur J Clin Microbiol Infect Dis, 2014. 33(10): p. 1757-62. 31. Dutch Working Party on Antibiotic Policy (Stichting Werkgroep Antibiotica Beleid [SWAB]). 2012. Guideline for the treatment of MRSA carriage. Secretariaat SWAB, Nijmegen, the Netherlands. 32. Ammerlaan, H.S., et al., Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis, 2009. 48(7): p. 922-30. 33. Parsons, J.B., et al., Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Host, Pathogen, and Treatment. Antibiotics (Basel), 2023. 12(3). 34. Jernigan, J.A., et al., Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med, 2020. 382(14): p. 1309-1319. 35. Bai, A.D., et al., Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clin Microbiol Infect, 2022. 28(8): p. 1076-1084. 36. Yousaf, A., G.L. Baird, and L. Mermel, Association of Infectious Disease Consultation With Clinical Outcomes in Patients With Staphylococcus aureus Bacteremia at Low Risk for Endocarditis. Open Forum Infect Dis, 2018. 5(7): p. ofy142. 37. Holland, T.L., C. Arnold, and V.G. Fowler, Jr., Clinical management of Staphylococcus aureus bacteremia: a review. Jama, 2014. 312(13): p. 1330-41. 38. Holmes, N.E., et al., Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia. BMC Infect Dis, 2018. 18(1): p. 107. 39. Minejima, E., et al., Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis, 2020. 70(4): p. 566-573. 40. Kuehl, R., et al., Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis, 2020. 20(12): p. 1409-1417.
RkJQdWJsaXNoZXIy MTk4NDMw